Treatment as Prevention—Where Next?

Current HIV/AIDS Reports

Volumn 11, Issue 4, 2014, Pages 496-504

  Hull, Mark ^a,b   Lange, Joep ^c   Montaner, Julio S G ^a,b  

^a BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Antiretroviral therapy; Care cascade; Millennium Development Goals; Treatment as Prevention

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; COST EFFECTIVENESS ANALYSIS; DISEASE TRANSMISSION; EPIDEMIC; HUMAN; MEN WHO HAVE SEX WITH MEN; MORTALITY; PATIENT CARE; REVIEW; SOCIAL DISCRIMINATION; STIGMA; HEALTH CARE DELIVERY; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS; MALE; ORGANIZATION AND MANAGEMENT; PATHOGENICITY;

ANTI-RETROVIRAL AGENTS; DELIVERY OF HEALTH CARE; HIV; HIV INFECTIONS; HUMANS; MALE;

EID: 84919478018     PISSN: 15483568     EISSN: 15483576     Source Type: Journal    
DOI: 10.1007/s11904-014-0237-5     Document Type: Review

References (42)

1. Hammer SM, Saag MS, Schechter M, Montaner JS, Schooley RT, Jacobsen DM, et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. Jama. 2006;296(7):827–43.
2. Gunthard HF, Aberg JA, Eron JJ, Hoy JF, Telenti A, Benson CA, et al. Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA panel. Jama. 2014;312(4):410–25.
3. WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach, 2013.
4. Fang CT, Hsu HM, Twu SJ, Chen MY, Chang YY, Hwang JS, et al. Decreased HIV transmission after a policy of providing free access to highly active antiretroviral therapy in Taiwan. J Infecti Dis. 2004;190(5):879–85.
5. Montaner JS, Hogg R, Wood E, Kerr T, Tyndall M, Levy AR, et al. The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. Lancet. 2006;368(9534):531–6.
6. Lima VD, Johnston K, Hogg RS, Levy AR, Harrigan PR, Anema A, et al. Expanded access to highly active antiretroviral therapy: a potentially powerful strategy to curb the growth of the HIV epidemic. J Infect Dis. 2008;198(1):59–67.
7. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet. 2009;373(9657):48–57.
8. Nakagawa F, Lodwick RK, Smith CJ, Smith R, Cambiano V, Lundgren JD, et al. Projected life expectancy of people with HIV according to timing of diagnosis. AIDS (London, England). 2012;26(3):335–43.
9. Samji H, Cescon A, Hogg RS, Modur SP, Althoff KN, Buchacz K, et al. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PLoS One. 2013;8(12):e81355. Updated evaluation of life expectancy of individuals accessing ART in the NA-ACCORD cohort.
10. WHO. Global update on the health sector, HIV. 2014.
11. UNAIDS. Treatment 2015. Available from www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2013/JC2484_treatment-2015_en.pdf. Accessed 22 Jul, 2015.
12. Murray CJ, Ortblad KF, Guinovart C, Lim SS, Wolock TM, Roberts DA, et al. Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990–2013: a systematic analysis for the Global Burden of Disease study 2013. Lancet. 2014;384(9947):1005–70. An important update evaluating current indicators of the HIV epidemic at a global level.
13. Walensky RP, Ross EL, Kumarasamy N, Wood R, Noubary F, Paltiel AD, et al. Cost-effectiveness of HIV treatment as prevention in serodiscordant couples. N Engl J Med. 2013;369(18):1715–25. Important analysis demonstrating cost-effectiveness of ART expansion in South Africa and India.
14. Townsend CL, Byrne L, Cortina-Borja M, Thorne C, de Ruiter A, Lyall H, et al. Earlier initiation of ART and further decline in mother-to-child HIV transmission rates, 2000–2011. AIDS (London, England). 2014;28(7):1049–57.
15. Nosyk B, Audoin B, Beyrer C, Cahn P, Granich R, Havlir D, et al. Examining the evidence on the causal effect of HAART on transmission of HIV using the Bradford Hill criteria. AIDS (London, England). 2013;27(7):1159–65.
16. Attia S, Egger M, Muller M, Zwahlen M, Low N. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS (London, England). 2009;23(11):1397–404.
17. Donnell D, Baeten JM, Kiarie J, Thomas KK, Stevens W, Cohen CR, et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet. 2010;375(9731):2092–8.
18. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505.
19. Montaner JS, Lima VD, Harrigan PR, Lourenco L, Yip B, Nosyk B, et al. Expansion of HAART coverage is associated with sustained decreases in HIV/AIDS morbidity, mortality and HIV transmission: the “HIV Treatment as Prevention” experience in a Canadian setting. PLoS One. 2014;9(2):e87872. Updated ecologic analysis of the association of expanded ART programs and decreasing HIV incidence in British Columbia, Canada.
20. Tanser F, Barnighausen T, Grapsa E, Zaidi J, Newell ML. High coverage of ART associated with decline in risk of HIV acquisition in rural KwaZulu-Natal, South Africa. Sci (New York, NY). 2013;339(6122):966–71. Similar analysis of the effects of ART expansion on HIV acquisition in a resource-limited setting.
21. Montaner JS, Lima VD, Barrios R, Yip B, Wood E, Kerr T, et al. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet. 2010;376(9740):532–9.
22. Gardner EM, McLees MP, Steiner JF, Del Rio C, Burman WJ. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis. 2011;52(6):793–800.
23. Vital signs: HIV prevention through care and treatment—United States. Mmwr. 2011;60(47):1618–23.
24. Nosyk B, Montaner JS, Colley G, Lima VD, Chan K, Heath K, et al. The cascade of HIV care in British Columbia, Canada, 1996–2011: a population-based retrospective cohort study. Lancet Infect Dis. 2014;14(1):40–9.
25. Muessig KE, Smith MK, Powers KA, Lo YR, Burns DN, Grulich AE, et al. Does ART prevent HIV transmission among MSM? AIDS (London, England). 2012;26(18):2267–73.
26. Baggaley RF, White RG, Boily MC. HIV transmission risk through anal intercourse: systematic review, meta-analysis and implications for HIV prevention. Int J Epidemiol. 2010;39(4):1048–63.
27. Jin F, Jansson J, Law M, Prestage GP, Zablotska I, Imrie JC, et al. Per-contact probability of HIV transmission in homosexual men in Sydney in the era of HAART. AIDS (London, England). 2010;24(6):907–13.
28. Rodger A, Bruun T, Cambiano V, al. e. HIV transmission risk through condomless sex if HIV+ partner on suppressive ART: PARTNER study. Program and abstracts of the 21st Conference on Retroviruses and Opportunistic Infections; Boston, Massachusetts. Abstract 153LB 2014.
29. Birrell PJ, Gill ON, Delpech VC, Brown AE, Desai S, Chadborn TR, et al. HIV incidence in men who have sex with men in England and Wales 2001–10: a nationwide population study. Lancet Infect Dis. 2013;13(4):313–8.
30. Brown AE, Gill ON, Delpech VC. HIV treatment as prevention among men who have sex with men in the UK: is transmission controlled by universal access to HIV treatment and care? HIV Med. 2013;14(9):563–70.
31. Phillips AN, Cambiano V, Nakagawa F, Brown AE, Lampe F, Rodger A, et al. Increased HIV incidence in men who have sex with men despite high levels of ART-induced viral suppression: analysis of an extensively documented epidemic. PLoS One. 2013;8(2):e55312. Thought-provoking model of HIV incidence in the MSM population in England.
32. Johnson AS, Hall HI, Hu X, Lansky A, Holtgrave DR, Mermin J. Trends in diagnoses of HIV infection in the United States, 2002–2011. Jama. 2014;312(4):432–4.
33. U.S. National Institutes of Health and the University of Minnesota Clinical and Translational Science Institute. The START study (Strategic Timing of Antiretroviral Treatment). 2012. http://clinicaltrials.gov/ct2/show/study/NCT00867048#locn. Accessed 22 Jul 2014.
34. Iwuji CC, Orne-Gliemann J, Tanser F, Boyer S, Lessells RJ, Lert F, et al. Evaluation of the impact of immediate versus WHO recommendations-guided antiretroviral therapy initiation on HIV incidence: the ANRS 12249 TasP (treatment as prevention) trial in Hlabisa sub-district, KwaZulu-Natal. South Africa: study protocol for a cluster randomised controlled trial. Trials. 2013;14:230.
35. Kitahata MM, Gange SJ, Abraham AG, Merriman B, Saag MS, Justice AC, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med. 2009;360(18):1815–26.
36. Mocroft A, Furrer HJ, Miro JM, Reiss P, Mussini C, Kirk O, et al. The incidence of AIDS-defining illnesses at a current CD4 count >/=200 cells/muL in the post-combination antiretroviral therapy era. Clin Infect Dis. 2013;57(7):1038–47.
37. Lodi S, Phillips A, Touloumi G, Geskus R, Meyer L, Thiebaut R, et al. Time from human immunodeficiency virus seroconversion to reaching CD4+ cell count thresholds <200, <350, and <500 cells/mm (3): assessment of need following changes in treatment guidelines. Clin Infect Dis. 2011;53(8):817–25.
38. Thirumurthy H, Chamie G, Jain V, Kabami J, Kwarisiima D, Clark TD, et al. Improved employment and education outcomes in households of HIV-infected adults with high CD4 cell counts: evidence from a community health campaign in Uganda. AIDS (London, England). 2013;27(4):627–34. Compelling argument for the secondary economic benefits of successful ART programs.
39. Thompson MA, Mugavero MJ, Amico KR, Cargill VA, Chang LW, Gross R, et al. Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an International Association of Physicians in AIDS care panel. Ann Intern Med. 2012;156(11):817–33.
40. Wood E, Kerr T, Marshall BD, Li K, Zhang R, Hogg RS, et al. Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study. BMJ. 2009;338:b1649.
41. Das M, Chu PL, Santos GM, Scheer S, Vittinghoff E, McFarland W, et al. Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco. PLoS One. 2010;5(6):e11068.
42. Hull MW, Montaner J. Antiretroviral therapy: a key component of a comprehensive HIV prevention strategy. Curr HIV/AIDS Rep. 2011;8(2):85–93.